argenx (ARGX) Stock Analysis
This is a peer-relative look at argenx (ARGX): its performance, risk, profitability, growth, financial strength, dividend, and valuation are each measured against its Pharmaceuticals, Biotechnology & Life Sciences peers, so every number reads in context rather than in isolation.
Company Profile
argenx (ARGX) trades as an ADR rather than ordinary local shares — read it with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | ARGX |
|---|---|
| Name | argenx SE American Depositary Receipt |
| Country/Region | Netherlands |
| GICS Sector | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology |
| GICS Sub-Industry | Biotechnology |
| Market Capitalization | 58.31 billion USD |
| Currency | USD |
| Exchange | Nasdaq |
| Listing Date | May 18, 2017 |
| Security Type | ADR |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | Current stock: ARGX | Industry group median |
|---|---|---|
| Total Return (1Y) | 11.91% | 24.62% |
| Total Return (3Y, Annualized) | 25.68% | 20.37% |
| Total Return (5Y, Annualized) | 24.22% | -4.02% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | Current stock: ARGX | Industry group median |
|---|---|---|
| Volatility (1Y, Annualized) | 37.87% | 66.36% |
| Beta (5Y) | 0.45 | 0.93 |
| Max Drawdown (5Y) | -38.20% | -80.19% |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | Current stock: ARGX | Industry group median |
|---|---|---|
| Sharpe Ratio (1Y) | 0.20 | 0.36 |
| Sortino Ratio (1Y) | 0.31 | 0.58 |
Profitability
ROE (TTM)
No usable ROE is available for argenx (ARGX) this period, so the shareholder-equity return read is skipped.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
Group distribution
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
- ARGX
- --
Largest peers
- LLY
- 86.02%
- NVS
- 24.33%
- AZN
- 22.57%
- JNJ
- 20.02%
- MRK
- 5.06%
- ARGX
- --
- ABBV
- --
Net Margin (TTM)
argenx (ARGX) keeps 31.73% of revenue as net profit on net margin, above the industry benchmark range. That is unusually strong bottom-line conversion, though tax effects, asset sales, or other one-off gains should be checked before treating it as durable.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
31.73%
Group distribution
- ARGX
- 31.73%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Largest peers
- LLY
- 31.90%
- ARGX
- 31.73%
- AZN
- 17.68%
- NVS
- 17.49%
- JNJ
- 16.20%
- ABBV
- 15.67%
- MRK
- 3.64%
Operating Margin (TTM)
argenx (ARGX) turns 36.27% of revenue into operating profit, putting operating margin in the upper peer quartile. Before financing and taxes enter the picture, the day-to-day business keeps more of each sales dollar than most industry peers.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
36.27%
Group distribution
- Max
- 83.12%
- ARGX
- 36.27%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Largest peers
- LLY
- 53.66%
- ABBV
- 39.59%
- ARGX
- 36.27%
- MRK
- 35.22%
- NVS
- 34.27%
- AZN
- 29.57%
- JNJ
- 25.74%
Profitability Metrics
| Metric | Current stock: ARGX | Industry group median |
|---|---|---|
| ROE (TTM) | -- | -26.66% |
| ROA (TTM) | -- | -12.50% |
| Net Margin (TTM) | 31.73% | 0.00% |
| Operating Margin (TTM) | 36.27% | 0.00% |
| Gross Margin (TTM) | 59.84% | 37.87% |
Growth
Revenue Growth
argenx (ARGX) grew revenue 89.64%, in the upper peer quartile. The top line is expanding faster than at most industry peers, which points to share gains or stronger pricing.
EPS Growth
argenx (ARGX) grew earnings per share 53.13%, roughly around the peer group's normal range. Bottom-line momentum looks broadly typical for the industry.
Growth Metrics
| Metric | Current stock: ARGX | Industry group median |
|---|---|---|
| Revenue Growth (YoY) | 89.64% | 11.45% |
| Revenue Growth (3Y CAGR) | 116.25% | 9.94% |
| EPS Growth (YoY) | 53.13% | 4.28% |
| EPS Growth (3Y CAGR) | -- | 4.17% |
Financial Strength
Current Ratio (MRQ)
No usable current ratio is available for argenx (ARGX) this period, so the short-term liquidity read is skipped.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
Group distribution
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
- ARGX
- --
Largest peers
- LLY
- 1.39
- MRK
- 1.35
- JNJ
- 1.02
- AZN
- 1.01
- NVS
- 0.88
- ABBV
- 0.87
- ARGX
- --
Debt / Equity (MRQ)
argenx (ARGX) has debt-to-equity ratio of 0.01, in the lower-leverage quartile for its industry. Borrowing is modest relative to equity compared with most peers, which can leave more flexibility through a cycle.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.01
Group distribution
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- ARGX
- 0.01
- Min
- 0.00
Largest peers
- NVS
- 1.29
- LLY
- 1.23
- MRK
- 1.20
- AZN
- 0.66
- JNJ
- 0.55
- ARGX
- 0.01
- ABBV
- --
Financial Strength Metrics
| Metric | Current stock: ARGX | Industry group median |
|---|---|---|
| Current Ratio (MRQ) | -- | 5.52 |
| Debt / Equity (MRQ) | 0.01 | 0.15 |
| Net Debt / EBITDA | -2.70 | 1.08 |
Dividends
Dividend Yield (TTM)
argenx (ARGX) pays no dividend, leaving dividend yield at 0.00% this period. Shareholders may still receive value through reinvestment or buybacks, but there is no dividend income to compare here.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
Group distribution
- ARGX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Largest peers
- NVS
- 2.88%
- ABBV
- 2.40%
- MRK
- 2.29%
- JNJ
- 1.94%
- AZN
- 1.73%
- LLY
- 0.49%
- ARGX
- 0.00%
Dividend Payout Ratio (TTM)
argenx (ARGX) paid no earnings out as dividends this period, leaving payout ratio at 0.00%. There is no dividend payout to size against earnings.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
Group distribution
- ARGX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Largest peers
- MRK
- 343.43%
- ABBV
- 117.35%
- NVS
- 90.46%
- JNJ
- 80.12%
- AZN
- 45.38%
- LLY
- 21.71%
- ARGX
- 0.00%
Dividend Metrics
| Metric | Current stock: ARGX | Industry group median |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
argenx (ARGX) trades at P/E ratio of 32.12, near the industry’s usual earnings multiple. The stock is not showing a clear peer discount or premium on trailing earnings.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
32.12
Group distribution
- Max
- 85.34
- Q3
- 43.46
- ARGX
- 32.12
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
Largest peers
- MRK
- 148.21
- ABBV
- 50.05
- LLY
- 43.95
- JNJ
- 41.92
- ARGX
- 32.12
- NVS
- 31.02
- AZN
- 26.37
P/S Ratio (TTM)
argenx (ARGX) trades at 9.86 on P/S ratio, roughly in the peer group’s normal range. The market is not making a strong cheap-or-rich statement about its revenue base.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
9.86
Group distribution
- Max
- 58.18
- Q3
- 25.77
- ARGX
- 9.86
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
Largest peers
- LLY
- 13.95
- ARGX
- 9.86
- ABBV
- 7.80
- JNJ
- 6.69
- MRK
- 5.37
- NVS
- 5.35
- AZN
- 4.63
P/B Ratio (MRQ)
argenx (ARGX) trades at 172.23 on P/B ratio, above the industry benchmark range. Investors are putting an unusually rich price on each dollar of book equity relative to peers.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
172.23
Group distribution
- ARGX
- 172.23
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Largest peers
- ARGX
- 172.23
- LLY
- 29.96
- NVS
- 8.25
- JNJ
- 8.16
- MRK
- 8.06
- AZN
- 5.59
- ABBV
- -112.34
Valuation Metrics
| Metric | Current stock: ARGX | Industry group median |
|---|---|---|
| P/E Ratio (TTM) | 32.12 | 26.69 |
| P/S Ratio (TTM) | 9.86 | 7.30 |
| P/B Ratio (MRQ) | 172.23 | 3.25 |
| Free Cash Flow Yield (TTM) | -- | -1.66% |